<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01305993</url>
  </required_header>
  <id_info>
    <org_study_id>SB injection-G002</org_study_id>
    <nct_id>NCT01305993</nct_id>
  </id_info>
  <brief_title>Evaluating the Safety and Efficacy of SB Injection in Patients With Advanced or Metastatic Gastric Cancer</brief_title>
  <official_title>Phase Ⅱ,Open Label Clinical Trial to Investigate Safety and Efficacy of SB Injection in Patients With Advanced and Metastatic Gastirc Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SBPharmaceutical IND, Co., LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SBPharmaceutical IND, Co., LTD</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine efficacy of SB injection in Gastric Cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All eligible patients will receive SB injection therapy for 6 cycles (14~21 days for each
      cycle). Efficacy will be evaluated every 3 cycles.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2011</start_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluating Tumor Response Rate</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Scores on the Visual Analog Scale</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evalute patient's performance by measuring Eastern Cooperative Oncology Group scale</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine duration of response rate by measuring time to progression</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Gastric Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB injection</intervention_name>
    <description>Infusion SBinjection of 21.87ml/m^2, IV route, 24times for 4 months</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of 18years or over

          -  Patients who had failed more than 1 cycle of standard therapy with advanced or
             metasatic stage and with measurable lesions

          -  Life expectancy &gt;/= 5 months

          -  Not available to any of resectable surgery or radiotherapy

          -  Patients with adequate organ(e.g. heart, kidney, liver)and bone marrow function, as
             defined by

               1. Absolute neutrophil count(ANC)&gt;/= 1.0 x 10^9/L, Platelet count &gt;/= 75 x 10^9/L

               2. Total bilirubin &lt; 2.0mg/dL

               3. Aspartate Aminotransferase(AST) and/or Alanine Aminotransferase(ALT) &lt; 5 x Upper
                  Limit Normal(ULN)

               4. creatinine &lt; 2 x ULN

          -  ECOG status 0 to 2

          -  Female volunteers admitted to the study must be using a reliable means of
             contraception and must have a negative blood or urine pregnancy test at least 7days
             ago

          -  Patients or their legal representatives who have signed the informed consent form.

        Exclusion Criteria:

          -  Known brain or spinal cord metastases

          -  Patients who have received chemotherapy within the previous 4 weeks

          -  Patients who have received radiotherapy related tp Gastric cancer within 4weeks

          -  Patients who have participated in other clinical study within the previous 4weeks

          -  Pregnancy (absence to be confirmed by ß-hCG test) or lactation period

          -  Human immunodeficiency virus(HIV) antibody (+)

          -  Have active infection or serious concomitant systemic disorder incompatible with the
             study

          -  Clinically hypertension or diabete mellitus not well controlled with medication

          -  Clinically significant cardiac disease(e.g. congestive heart failure, symptomatic
             coronary artery disease and cardiac arrhythmias) or myocardial infarction

          -  Presence or history of malignancy other than Gastirc cancer within 5years

          -  Have severe Neurologic or psychological disorder

          -  Patients who have history of allery with this investigational drug(SB injection)

          -  Obvious cognitive or physical impairment that would prevent participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong-oon Shin, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inha University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yong-oon Shin, Prof.</last_name>
    <phone>032-890-2548</phone>
    <email>ywshin@inha.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ji-yeon Lee, RN/BSc</last_name>
    <phone>032-890-1133</phone>
    <email>twindleclara@inha.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <state>Jung-gu</state>
        <zip>400-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yong-oon Shin, Prof.</last_name>
      <phone>032-890-2548</phone>
      <email>ywshin@inha.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Ji-yeon Lee, RN/BSc</last_name>
      <phone>032-890-1133</phone>
      <email>twinkleclara@inha.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.sbp.com/</url>
    <description>SBP</description>
  </link>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2011</study_first_submitted>
  <study_first_submitted_qc>February 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2011</study_first_posted>
  <last_update_submitted>February 27, 2011</last_update_submitted>
  <last_update_submitted_qc>February 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Lee Dong-heum / executive director</name_title>
    <organization>SBPharmaceutical IND, Co., LTD</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

